The Beacon Aqueous Microshunt is an investigational device. This website will give a preview of what we hope Beacon will do for glaucoma sufferers after we’ve completed our clinical trial work and other testing.

Adobe Stock 167244463

Animals Experience Glaucoma Too

MicroOptx believes its core technology, utilized to treat human glaucoma patients, may also be of benefit to animals with glaucoma. Through large clinical trials as well as collaboration with key investigator veterinary ophthalmologists throughout the world, MicroOptx is working to improve patient outcomes.

Every Dog Deserves Its Day

MicroOptx is developing SalVO – a novel ab externo Minimally Invasive Glaucoma Surgery (MIGS) micro implant for the treatment of glaucoma in dogs. The device is very small, engineered and manufactured by micro-engineering and nanotechnology. It is the first of its kind to be specifically designed for canine glaucoma patients.

Our Hero, Lilly

On April 5. 2018 Lilly made medical history by becoming the World’s first patient to receive SalVO and demonstrate that it is possible to stop the ravages of glaucoma. Her participation in the Veterinary Glaucoma Implant Registry (VIGOR) Clinical Trial has paved the way for a new generation of glaucoma care for animals and humans alike. At MicroOptx, Lilly will always be number one, forever remembered and loved.

Like Details? We've Got Them.

SalVO utilizes a 39 µm diameter hydrogel channel to guide aqueous humor (AH) from the anterior chamber to the surface of the eye. The small diameter of the channel is calculated to provide the required resistance to AH flow for optimal intraocular pressure (IOP) reduction. SalVO is the only MIGS device that can precisely control the rate of aqueous outflow – it is engineered to lower the IOP to threshold (12 mmHg or less), relieving pathologic pressure on the optic nerve. It is the only MIGS device that shunts AH directly to the tear film on the surface of the eye.

Status of Device Evaluation in Canines

SalVo is not commercially available. It is currently under evaluation by key veterinary ophthalmologists.